Neal Shore, MD, FACS, highlights the efficacy data from the EMBARK study, toxicities observed with enzalutamide alone or in combination with a LHRH agonist, and the significance of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.